Independent fund research. Built on SEC filings.

How we research funds

ETF · Health Care Sector · iShares

iShares Genomics Immunology and Healthcare ETF (IDNA)

Ticker IDNA · Since 2019-06-11 · · Holdings as of Jul 31, 2026

Expense ratio
0.47%$47/yr per $10k
5-yr return
−4.8%annualized
1-yr return
−1.0%as of Dec 2024
Net assets
$190.9Mall share classes
Holdings
61

Bottom line

Is IDNA a good fund? The bottom line

IDNA is a managed health care sector ETF from iShares.

It charges 0.47% — about $47 a year on every $10,000 invested, cheaper than 83% of health care sector funds we track.

It returned −1.0% over one year, −4.8% a year over five years (as of Dec 31, 2024, per its prospectus).

With $191 million in net assets and 61 holdings, its largest position is BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares (10.4%) and the top 10 make up 49.5% of the portfolio.

What stands out

  • Low cost: cheaper than 83% of health care sector peers

What to watch

  • 5-year return in the bottom quarter of its category

Updated Nov 19, 2026

What IDNA invests in

The iShares Genomics Immunology and Healthcare ETF (the Fund ) seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering.

The Fund seeks to track the investment results of the NYSE FactSet Global Genomics and Immuno Biopharma Index ? (the Underlying Index ), which measures the performance of equity securities issued by companies in the biopharmaceutical and healthcare equipment and services industries that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering, as determined by ICE Data Indices, LLC or its affiliates (the Index Provider or IDI ). The Underlying Index is composed of equity securities primarily listed in one of 42 developed and emerging market countries. Companies must have equal to or greater than 50% of their revenue from one or more selected Level 6 industries, as defined by the FactSet Revere Business Industry Classification System ( RBICS ), which includes biopharmaceutical industries, healthcare equipment industries, and healthcare services…

From the fund's prospectus (filed Nov 21, 2025).

IDNA performance

Fund calendar-year total returns, 2020–2024 2020: +54.5%; 2021: −4.0%; 2022: −42.1%; 2023: −7.8%; 2024: −1.0% +54.5% 2020 −4.0% 2021 −42.1% 2022 −7.8% 2023 −1.0% 2024
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
IDNA−1.0%−4.8%—
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2024

Full IDNA performance history →

What IDNA costs

On a $10,000 investment, IDNA's 0.47% expense ratio costs about $47 a year. The prospectus estimates $591 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full IDNA fee table →

IDNA top 10 holdings

#Holding% of fund
1BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares10.39%
2Bayer Aktiengesellschaft4.81%
3Twist Bioscience Corp4.79%
4Revolution Medicines, Inc.4.55%
5Regeneron Pharmaceuticals, Inc.4.35%
6Genmab A/s4.23%
7Incyte Corporation4.23%
8Moderna, Inc.4.19%
9Takeda Pharmaceutical Company Limited4.05%
10Merck & Co., Inc.3.91%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 49.5% of the fund. See all top 25 holdings and asset mix →

Alternatives to IDNA

More funds like IDNA →

IDNA FAQ

What is the expense ratio of IDNA?
IDNA's expense ratio is 0.47%, which works out to about $47 a year for every $10,000 invested. The prospectus estimates total costs of $591 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is IDNA a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 83% of health care sector peers; 5-year return in the bottom quarter of its category. This is general information, not personalized advice.
What does IDNA hold?
IDNA's largest holdings are BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency Shares (10.4%), Bayer Aktiengesellschaft (4.8%), Twist Bioscience Corp (4.8%), Revolution Medicines, Inc. (4.6%), Regeneron Pharmaceuticals, Inc. (4.4%). It holds 61 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is IDNA's 5-year return?
IDNA returned −4.8% a year over the five years ending Dec 31, 2024. Past performance does not guarantee future results.
Who manages IDNA?
IDNA is offered by iShares through iSHARES TRUST.